LOUISVILLE, Ky. & NEW YORK--(BUSINESS WIRE)-- Humana Inc. (NYSE:HUM - News) and Pfizer Inc. (NYSE:PFE - News) today announced a five-year research partnership to explore new ideas and ways to improve the quality, outcomes and costs of the health care delivery system for senior citizens and other populations.
Humana, one of the nation’s largest health care companies, and Pfizer, the world’s largest biopharmaceutical company, will bring together researchers and health care experts from both organizations to study key issues and deliver interventions to reduce inefficiencies in the management of chronic conditions such as pain, cardiovascular disease, and Alzheimer’s disease. This collaboration will leverage Humana’s experience with making health care more affordable for seniors and Pfizer’s expertise in researching and developing medicines to treat chronic conditions- bringing together data and scientific information to better understand patient needs and the effectiveness of treatments.
“This research collaboration is yet another important strategy Humana has implemented to learn more about our members’ health and well-being,” said William Fleming, Pharm.D., vice president of Humana Pharmacy Solutions. “We are excited about this long-term research collaboration with Pfizer as the companies strive to develop an important body of knowledge that may meaningfully advance the work of our respective companies in various disease areas, population health sub-types, and intervention methods, among other things.”
Humana, working through its research affiliate Competitive Health Analytics, Inc., and Pfizer share a vision of building on clinical evidence using real world data and comparative effectiveness research to better understand patient needs and improve access to appropriate care so that the right services are delivered to the right patients at the right time.
“Through this innovative partnership we hope to improve outcomes and health for patients,” said Steven Romano, MD, senior vice president of Pfizer’s Primary Care Medicines Development Group. “Together we will strive to find new solutions to address the issues of chronic illnesses that are treated in the primary care setting.”
According to the U.S. Census Bureau Population Projections, over the next 10 years the Medicare-eligible population is expected to grow to 65 million – a 36 percent increase from 2010. With this significant and growing population, along with the need to more efficiently use health care resources and reduce costs, it makes sense for two leading health care companies to join forces and address these challenges.
Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.
Humana Inc., headquartered in Louisville, Kentucky, is a leading healthcare company that offers a wide range of insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being. By leveraging the strengths of its core businesses, Humana believes it can better explore opportunities for existing and emerging adjacencies in healthcare that can further enhance wellness opportunities for the millions of people across the nation with whom the company has relationships.
More information regarding Humana is available to investors via the Investor Relations page of the company’s web site at www.humana.com, including copies of:
•Annual reports to stockholders
•Securities and Exchange Commission filings
•Most recent investor conference presentations
•Quarterly earnings news releases
•Replays of most recent earnings release conference calls
•Calendar of events (including upcoming earnings conference call dates and times, as well as planned interaction with research analysts and institutional investors)
•Corporate Governance information
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50028674&lang=en
MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50028674<=en
Humana Corporate CommunicationsMarvin Hill, email@example.comPfizer Inc.MacKay Jimeson, 212-733-2324Media RelationsMacKay.Jimeson@pfizer.com